Nonmalignant Hematology Disorders

Expert faculty review and share their insights on key findings in nonmalignant hematologic disorders presented at the 2023 ASH Annual Meeting.

Share

Program Content

Activities

  • Nonmalignant Hematology Disorders
    Conference to Clinic: Nonmalignant Hematology Disorders
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 08, 2024

  • ASH 2023: Nonmalignant Hematology
    Key Studies in Nonmalignant Hematology Disorders: Independent Conference Coverage of ASH 2023
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 22, 2024

    Expires: February 21, 2025

Activities

Lovo-cel in SCD Pooled Analysis
Pooled Analysis of Phase I/II and Phase III Trials of Lovotibeglogene Autotemcel Gene Therapy in Patients With Sickle Cell Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

BMT CTN 1507 RIC BMT SCD
BMT CTN 1507: Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults With Severe Sickle Cell Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

APPLY-PNH Final Results
APPLY-PNH Final 48-Wk Results: Phase III Trial of Iptacopan Monotherapy in Patients With PNH and Residual Anemia With Anti-C5 Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Sutimlimab in CAD Safety Analysis
Pooled Post Hoc Analysis of Safety Outcomes From Phase III CARDINAL and CADENZA Trials of Sutimlimab in Cold Agglutinin Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

PNH ALPHA Study
ALPHA: Phase III Long-term Data for Ravulizumab or Eculizumab With Add-on Danicopan or Placebo in Patients With PNH and cs-EVH
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

REACH: Hydroxyurea for SCA
REACH: Long-term Analysis of Dose-Optimized Hydroxyurea for Treatment of Pediatric Patients With Sickle Cell Anemia in Sub-Saharan Africa
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

Faculty

cover img faculity

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.